Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value
Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln
Brief: Beyondspring Presents Efficacy/Safety Results From A Phase 2 Study Of Pembrolizumab Plus Plinabulin/Docetaxel In Metastatic Nsclc After Progressing On First-Line Immune Checkpoint Inhibitors At Esmo Congress 2024
Brief: Beyondspring Inc Files For Stock Shelf Offering Of Up To 10 Million Ordinary Shares- SEC Filing
Brief: BeyondSpring Announces First Patient Dosed In Phase 2 Study Of First-Line Extensive-Stage Small-Cell Lung Cancer
Brief: Beyondspring Regains Compliance With Nasdaq Minimum Bid Price And Periodic Filing Requirements
Brief: Beyondspring Says Arbitral Tribunal At China International Economic And Trade Arbitration Committee Issued Final Award On Arbitration Initiated By Hengrui
Brief: Beyondspring Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Beyondspring Says Hengrui Initiated Arbitration Proceeding With China International Economic And Trade Arbitration Committee
Brief: BeyondSpring Reports Data From Phase 1 Investigator Initiated Study Show Reduction In Chemotherapy-Induced Infectious Neutropenic Fever With Plinabulin
U.S. RESEARCH ROUNDUP-E2open, Molson Coors Beverage Co, Premier
Brief: BeyondSpring Reports Year End 2022 Financial Results
Beyondspring Inc expected to post earnings of 48 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, Five Below, Lennar
Brief: BeyondSpring Says Co's Chinese Unit Withdrew NDA Submission
Brief: Beyondspring Enrolls First Patient In Mid-stage Lung Cancer Study